FTSE Italy Government Bond Index (ITGOVP01) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th...

Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan

Beasley Allen, Levin Papantonio, and coalition of law firms cite misleading efforts to secure approval Thousands of individuals who are being...

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for...

Form 8-K - Current report

Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop

U.S. index futures are registering a significant drop in pre-market trading this Wednesday, with the...

Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates

Spirit Airlines (NYSE:SAVE) – Spirit Airlines reduced its revenue forecast for the second quarter to...

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24...

Johnson & Johnson reports Q2 2024 results

2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5...

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is...

Form 4 - Statement of changes in beneficial ownership of securities

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the...

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement...

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest...